Gonçalves, LisaGoncalves, DuarteCasanelles, Teresa EstebanGuerra, Laura PratasMenezes, Maria B.Branco, Vanessa DuarteLuís, Joana AlvesSimões, FilipaGramaça, JoãoPinho, Inês S.Barroso, TiagoPatel, VanessaMartins, Miguel EsperançaBrás, Raquel LopesSousa, Rita Teixeira deMansinho, AndréTorres, SofiaCosta, Luis2024-12-062024-12-062024-06-010732-183Xhttp://hdl.handle.net/10400.1/26413Immune checkpoint inhibitors (ICI) targeting programmed cell death protein 1 (PD-1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) are now the standard of care in the treatment of metastatic melanoma (mM). The interplay between cancer cells and tumor microenvironment cells (e.g. immune cells) impacts cancer cell survival, local invasion, and metastatic dissemination. Chrono-immunotherapy is an emerging field as circadian oscillations are observed in the immune landscape (e.g immune cell numbers) as well as in the expression of immunotherapy targets (e.g. PD-1).engconference object10.1200/jco.2024.42.16_suppl.95421527-7755